|  | Non EU/EFTA n=16 (%) | EU/EFTA n=28 (%) | P-value |
---|---|---|---|---|
National coordination | Have viral hepatitis programme activities address PWID as a specific population | 10 (63) | 22 (79) | 0.512 |
 | Have a written national viral hepatitis prevention & control strategy which also targets ID use | 6 (38) | 6 (21) | 0.335 |
Axis 1 | Held events for World Hepatitis Day 2012 | 7 (44) | 10 (36) | 0.765 |
 | Funded viral hepatitis awareness campaigns focusing on harm reduction for PWID (other than World Hepatitis Day) | 5 (31) | 5 (18) | 0.404 |
Axis 2 | Conduct regular serosurveys among PWID | 6 (38) | 6 (21) | 0.639 |
Axis 3 | Have a national policy for prevention & control of viral hepatitis among PWID | 9 (56) | 16 (57) | 0.954 |
Axis 4 | Have HBV & HCV testing which is: | Â | Â | Â |
 | • Free of charge for all | 6 (38) | 14 (50) | 0.569 |
 | • Free of charge for PWID | 2 (13) | 4 (14) | 0.423 |
 | Have publicly funded treatment for HBV | 9 (56) | 27 (96) | 0.004* |
 | HBV Drugs on national essential medicines list or subsidized by government: |  |  |  |
 | • Interferon alpha | 12 (75) | 22 (79) | 0.786 |
 | • Pegylated interferon | 11 (69) | 22 (79) | 0.469 |
 | • Lamivudine | 13 (81) | 24 (86) | 0.697 |
 | • Adefovir dipivoxil | 4 (25) | 20 (71) | 0.003* |
 | • Entecavir | 3 (20) | 19 (68) | 0.002* |
 | • Telbivudine | 4 (25) | 13 (46) | 0.160 |
 | • Tenofovir | 8 (50) | 19 (68) | 0.242 |
 | Have publicly funded treatment for HCV | 9 (56) | 26 (93) | 0.010* |
 | HCV Drugs on national essential medicines list or subsidized by government: |  |  |  |
 | • Interferon alpha | 8 (50) | 22 (79) | 0.050* |
 | • Pegylated interferon | 12 (75) | 23 (82) | 0.572 |
 | • Ribavirin | 14 (88) | 24 (86) | 0.868 |
 | • Boceprevir | 2 (13) | 15 (54) | 0.007* |
 | • Telaprevir | 3 (19) | 14 (50) | 0.041* |